According to the Zhitong Finance App, Weijun Biotechnology (00660.HK) announced its annual results for the year ended June 30, 2026, with revenue of HK$405 million, up 7.3% year on year; profit attributable to company owners of HK$7.205 million, loss of HK$146.23 million for the same period last year; basic profit per share of HK$3.40 cents.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.